The most commonly reported side effects of albumin chromated cr-51 serum include colitis ischaemic, restlessness, and self injurious behaviour, based on 5 FDA adverse event reports from 2011 to 2025.
Percentages show how often each reaction appears relative to total reports for albumin chromated cr-51 serum.
These are voluntary reports and do not establish that albumin chromated cr-51 serum caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside albumin chromated cr-51 serum. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
40.0% of albumin chromated cr-51 serum adverse event reports involve female patients and 40.0% involve male patients. The largest age group is elderly at 80%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking albumin chromated cr-51 serum when the adverse event was reported.
Albumin Chromated Cr-51 Serum is sold under the brand name Chromalbin.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.